The South Korea non-alcoholic steatohepatitis therapeutics (NASH) market size stood at around USD xx billion in 2019 and is projected to reach xx billion by 2028, exhibiting a CAGR of around 6.5% during the forecast period.
The prevalence of non-alcoholic fatty liver disease (NAFLD) in Korea is about 30 percent. NAFLD progresses into NASH. Non-alcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic or consume little alcohol. NASH is one of the common liver diseases, often called silent liver disease. It is characterized by cell injury, inflammatory cell infiltration and hepatocyte ballooning that may further progress to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
NASH is expected to surpass hepatitis C virus infection as the leading aetiology of end-stage liver disease requiring liver transplantation in coming years. It is also currently the leading aetiology driving the burden of hepatocellular carcinoma.
Increase in prevalence of NASH, strong presence of ideal pipeline molecules, higher number of unmet needs, and growth in awareness of NASH therapeutics will fuel the market drive of NASH therapeutics during the forecasted period.
Furthermore, rise in prevalence of chronic diseases like diabetes and obesity, is expected to influence the market growth. On the other hand, lack of diagnostic technologies for NASH limit the growth of the market.